Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system

OBJECTIVES: To evaluate the cost-effectiveness of biologics and methotrexate (MTX) for rheumatoid arthritis (RA) using the number needed to treat (NNT) concept and total actual health care cost. METHODS: This study included 121 RA patients with newly prescribed biologics and/or MTX between 2012 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Harigane, Kengo, Mochida, Yuichi, Shimazaki, Takayuki, Kobayashi, Naomi, Inaba, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944043/
https://www.ncbi.nlm.nih.gov/pubmed/35331233
http://dx.doi.org/10.1186/s12962-022-00347-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944043/
https://www.ncbi.nlm.nih.gov/pubmed/35331233
http://dx.doi.org/10.1186/s12962-022-00347-2

Ejemplares similares